C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. The cancer intelligence company is developing a platform that can perform whole-genome sequencing using only 2 milliliters of blood. Its ultra-sensitive liquid biopsy assay allows physicians to monitor patient treatment response and detect treatment failure or disease recurrence months and potentially years earlier than current monitoring methods. C2i’s cancer diagnostics service uses artificial intelligence pattern recognition and the whole-genome analysis to spot trace amounts of cancer much quicker, in about a week, to inform better treatment decisions and ultimately save lives. The company aims to help patients avoid unnecessary overtreatment with toxic chemotherapy or radiation, as well as to prevent them from going without treatment while cancer quietly grows and metastasizes. In 2019, Boris Oklander, Asaf Zviran, and Ezra Sofer established the company in New York, New York.

Healx integrates artificial intelligence with expert pharmacology to discover new treatments for rare diseases and to accelerate them into clinical trials within 2 years. To achieve this, Healx has developed the most comprehensive AI-based drug discovery platform for rare diseases: HealNet. HealNet disrupts the conventional process of drug discovery, reducing the costs, time and risk of bringing new therapies to market. Our plan is to have 100 treatments for rare diseases in development by 2025.

Healx integrates artificial intelligence with expert pharmacology to discover new treatments for rare diseases and to accelerate them into clinical trials within 2 years. To achieve this, Healx has developed the most comprehensive AI-based drug discovery platform for rare diseases: HealNet. HealNet disrupts the conventional process of drug discovery, reducing the costs, time and risk of bringing new therapies to market. Our plan is to have 100 treatments for rare diseases in development by 2025.